PositiveID’s Caregiver Non-Contact Thermometer Outperforms in Evidence-Based Study

DELRAY BEACH, Fla., July 25, 2016 (GLOBE NEWSWIRE) -- PositiveID Corporation (“PositiveID” or “Company”) (OTCQB:PSIDD), a life sciences company focused on detection and diagnostics, announced today its FDA-cleared Caregiver® non-contact thermometer outperformed a temporal artery thermometer in every category evaluated during a Veterans Affairs San Diego Healthcare System study of Post Anesthesia Care Unit (“PACU”) patients.

In the evidence-based study of 40 patients, PACU nurses evaluated the Caregiver thermometer and a temporal artery thermometer within the following categories: ease-of-use, speed, reliability, patient comfort, ease of care, and overall performance. In every category studied, the Caregiver no-touch thermometer outperformed the temporal artery thermometer.

The goals of the study, To Touch or Not to Touch? That is the Question; Using the Evidence to Change Thermometry Practice, were to determine if a temporal artery thermometer and the Caregiver non-contact thermometer compare favorably to an oral thermometer, and allow PACU nurses to determine their thermometer preference and recommend a practice change. In the study, patients had their temperature recorded using an oral electronic thermometer, a tympanic and temporal artery thermometer, and the Caregiver no-touch forehead thermometer. While the tympanic and temporal artery thermometer and Caregiver were all found to be clinically acceptable, the PACU staff unanimously agreed to move forward with the Caregiver thermometer due to ease of use.

“We routinely receive positive feedback from healthcare practitioners who use our Caregiver thermometer for its accuracy, reliability and ease of use,” stated William J. Caragol, Chairman and CEO of PositiveID. “We are very pleased with the results of this evidence-based study, which, we believe not only further substantiate the value proposition of Caregiver with hard data, but also highlight the benefits of using Caregiver particularly in certain patient populations.”

Caregiver, which is FDA-cleared for clinical use, utilizes infrared technology for measurement of forehead temperature in adults, children, and infants without contact. The Caregiver thermometer has documented clinical precision and is capable of high-volume use. The device meets all ASTM specifications for use in a clinical setting.

The authors of the Evidence-Based Practice Institute study were John Shurilla-Finnigan, RN, BSN, and Mary Beth Tucker, APRN, CCNS of the VA San Diego Healthcare System, San Diego, CA. This material is the result of work supported with the resources and the use of facilities at the VA San Diego Healthcare System, San Diego, CA. The contents do not represent the views of the U.S. Department of Veterans Affairs or the United States Government.

The study summary may be found at www.thermomedics.com/clinical-studies/.

About PositiveID Corporation
PositiveID Corporation is a life sciences tools and diagnostics company with an extensive patent portfolio. PositiveID develops biological detection and diagnostics systems, specializing in the development of microfluidic systems for the automated preparation of and performance of biological assays. PositiveID is also a leader in the specialty vehicle market, with a focus on mobile labs. For more information on PositiveID, please visit http://www.psidcorp.com, or connect with PositiveID on Twitter, Facebook or LinkedIn.

Statements about PositiveID's future expectations, including the likelihood that the results of this evidence-based study further substantiate the value proposition of Caregiver with hard data; the likelihood that the results of the study highlight the benefits of using Caregiver particularly in certain patient populations; constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company’s ability to target the professional healthcare market, as well as other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on April 12, 2016, and 10-Qs filed on May 16, 2016, November 12, 2015, and August 13, 2015, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Contacts: PositiveID Corporation Allison Tomek (561) 805-8044 atomek@positiveidcorp.com RedChip Companies Jon Cunningham (407) 644-4256 jon@redchip.com

Source:PositiveID Corporation